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Objectives
The aim of the study was to assess the impact of the gain in body mass index (BMI) observed
immediately after antiretroviral therapy (ART) initiation on the subsequent risk of cardiovascular
disease (CVD) and diabetes.
Methods
We analysed data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort
study. Outcomes were development of (i) CVD (composite of myocardial
infarction/stroke/coronary procedure) and (ii) diabetes. The main exposure variable was change
in BMI from ART initiation (pre-ART) to 1 year after initiation (continuous variable) in
treatment-naïve individuals initiating ART with no history of CVD or diabetes (for respective
outcomes). BMI [weight (kg)/(height (m))2] was categorized as underweight (< 18.5), normal
(18.5–25), overweight (25–30) and obese (> 30). Poisson regression models were fitted stratified
for each pre-ART BMI category to allow for category-specific estimates of incidence rate ratio
(IRR). Models were adjusted for pre-ART BMI and CD4 count, key known risk factors
(time-updated where possible) and calendar year.
Results
A total of 97 CVD events occurred in 43 982 person-years (n = 9321) and 125 diabetes events in
43 278 person-years (n = 9193). In fully adjusted analyses for CVD, the IRR/unit gain in BMI
(95% confidence interval) in the first year of ART, by pre-ART BMI category, was: underweight,
0.90 (0.60–1.37); normal, 1.18 (1.05–1.33); overweight, 0.87 (0.70–1.10), and obese, 0.95
(0.71–1.28) (P for interaction = 0.04). For diabetes, the IRR/unit gain in BMI was 1.11 (95%
confidence interval 1.03 to 1.21), regardless of pre-ART BMI (P for interaction > 0.05).
Conclusions
Short-term gain in BMI following ART initiation appeared to increase the longer term risk of
CVD, but only in those with pre-ART BMI in the normal range. It was also associated with
increased risk of diabetes regardless of pre-ART BMI.
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Introduction
Excess body weight is known to be an important risk factor
for the development of cardiovascular diseases (CVDs) and
diabetes mellitus (DM) in the general population, and is
now a growing concern in HIV-positive individuals receiv-
ing antiretroviral therapy (ART) [1–3]. Many HIV-positive
individuals initiating ART experience a significant gain in
weight, irrespective of their weight at the time of starting
ART [1,4–6]. With the move towards earlier start of ART,
most patients are likely to start ART at “normal” to “over”
weight. Further weight gain in such individuals could be of
detriment to their future health.
In a large cohort (1917 study), mean body mass index
(BMI) at ART initiation was 25.4 kg/m2 with 40% of
patients being overweight or obese [1]. Further, 20% of
patients moved from the overweight to the obese BMI
category following ART initiation [1]. In a large Veterans’
Affairs (VA) cohort, HIV-positive veterans had gained sig-
nificantly more weight at 1 year of ART compared with
HIV-negative controls [7]. Further, this weight gain was
more strongly associated with risk of incident DM in HIV-
positive individuals (10% more risk per 5 lb gain) compared
with HIV-negative individuals (6% more risk per 5 lb gain)
[7]. A nested analysis in the same cohort found that the
median BMI post-ART was about 1.3 units higher than
pre-HIV levels in the same group of individuals [8].
Better understanding of the relevance of weight changes
around ART initiation in terms of long-term health is
clearly needed. If it is found to be an important contributor
to the development of clinical events, it could help better
strategize risk factor management in this population.
In this paper, we analysed the data from the Data Col-
lection on Adverse Events of Anti-HIV Drugs (D:A:D)
study, a study of a large heterogeneous cohort with well-
validated outcomes, to assess the relationship between
short-term BMI gain after ART initiation and the subse-
quent risk of two clinical outcomes, CVD and DM.
Methods
Study population
The design of the D:A:D study has been described in detail
elsewhere [9]. In brief, it is an observational study of
> 49 000 HIV-positive people under care for HIV infection
from 11 cohorts from Europe, Australia, and the USA. All
participants were under active follow-up in their cohorts at
the time of enrolment in the study. The primary study aim
was to investigate the associations between use of
antiretroviral drugs and risk of CVD and other major clini-
cal events. Data are collected prospectively during routine
clinic visits; the standardized data set includes information
on demographic factors, AIDS-related events and deaths,
known risk factors for CVD, laboratory markers for moni-
toring HIV infection and CVD, ART, and treatments that
influence CVD risk. Information on all incident cases of
CVD is reported to the study coordinating centre for vali-
dation and coding which is performed blind to the patient’s
ART status.
For this analysis, we selected the subset of D:A:D
patients who (i) were known to be ART-naïve at cohort
entry and started ART (defined as at least three agents) at
some point over follow-up; and (ii) had BMI [weight (kg)/
(height (m))2] measurements available at ART initiation
(closest measurement within last 365 days before ART
initiation), which we refer to as pre-ART BMI, and at 1 year
after initiation of ART (closest measurement within ± 180
days), which we refer to as post-ART BMI.
Study outcomes
The main clinical outcomes were: (i) CVD, defined as the
composite of myocardial infarction (MI), sudden cardiac
death or invasive procedure (coronary artery bypass graft,
carotid endarterectomy or angioplasty), or confirmed
stroke; and (ii) DM, a protocol-defined D:A:D secondary
endpoint. In summary, the definition of DM comprises
either fasting glucose > 7.0 mmol/L on at least two occa-
sions or a single value of NGSP haemoglobin A1c > 6.5%,
or symptoms with a random glucose > 11.1 mmol/L, or 2-h
oral glucose tolerance test > 11.1 mmol/L, or use of anti-
diabetic drugs (see also http://www.cphiv.dk for details of
outcome validation). The main objective was to assess the
relationship between change in BMI from pre-ART to 1
year post ART initiation (called “BMI change”) and the
outcomes, and whether it varied by pre-ART BMI. Given
that both the CVD and DM outcomes have their own set of
established risk factors, the two outcomes were analysed
separately.
Statistical methods
We first assessed factors independently associated with
change in BMI at 1 year post ART initiation. For this, we
used linear regression models. We chose the variables to be
included in a multivariable model using backward elimi-
nation (P < 0.05 as cut-off for retention). The following
variables were considered: pre-ART BMI, age, gender, race
(white or other), mode of HIV transmission, CD4 count at
ART initiation, smoking (current, past, never or unknown)
and use of protease inhibitor (PI) or nonnucleoside reverse
transcriptase inhibitor (NNRTI) class in the initial regimen.
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We also plotted mean change in BMI over years 1 to 5 post
ART initiation to visually assess trends over time.
For the clinical outcomes, Poisson regression models
were used. Follow-up time for the analysis started from the
1 year post ART initiation time-point until the earliest of a
new event, death or February 2013 (Fig. 1). We excluded
patients who were known to have developed CVD (for CVD
analyses) and those with DM (for DM analyses) any time
prior to or until 1 year after ART initiation.
Pre-ART BMI (kg/m2) was used to categorize each indi-
vidual as underweight (< 18.5), of normal weight (18.5-
<25), overweight (25-<30) or obese (>=30) [i.e. World
Health Organization (WHO) classification [10]]. Additional
analyses were also performed in which (i) the pre-ART BMI
was categorized in quartiles, because of the lack of con-
sensus on ideal cut-offs [11] and also to make the distri-
bution in the categories even; and (ii) the normal weight
category was further subdivided as 18.5 to <22 (normal
weight, low) and 22 to <25 (normal weight, high) kg/m2.
After initial assessment of event rates by quartiles of
change in BMI within pre-ART BMI categories, we decided
to model BMI change as a continuous variable to model the
linear increase in rates.
Given that the impact of weight gain could potentially
be different by the pre-ART BMI, we assessed whether
pre-ART BMI was an effect modifier for each of the out-
comes by fitting an interaction term.
Models were sequentially adjusted for previously estab-
lished risk factors in the D:A:D study for each of the
outcomes [12,13]. For CVD, models initially adjusted for
pre-ART BMI, sex, mode of transmission, family history of
CVD, and age and smoking status as measured at analysis
entry. Next, models additionally adjusted for DM, total and
high-density lipoprotein (HDL) cholesterol, systolic blood
pressure, current abacavir, and cumulative use of lopinavir/
ritonavir and indinavir as measured at analysis entry [12].
Finally, models adjusted for all of these variables (including
specific ART agents mentioned above) and calendar year in
a time-updated fashion where possible. Similarly, for DM,
initial models adjusted for pre-ART BMI, gender, mode of
transmission, hepatitis C virus coinfection status as known
at cohort entry, and age at analysis entry. Next, additional
adjustment was performed for lipodystrophy, triglycerides,
HDL cholesterol and blood pressure as measured at analysis
entry, and then fully time-updated where possible (as well
as calendar year). Such sequential adjustment allowed us to
see the effect of factors potentially on the causal pathway
between the BMI change and the outcome (e.g. lipids and
blood pressure). All models for both the outcomes were
additionally adjusted for the CD4 count at ART initiation,
and clinical cohort (to account for any cohort-level
factors). We did not adjust for concomitant lipid and blood
pressure medications to avoid over-adjustment, as the
actual time-updated lipid and blood pressure values were
available.
We conducted the following sensitivity analyses: (1)
including only those with viral load < 400 HIV-1 RNA
copies/mL at 1 year post-ART; (2) excluding those report-
Fig. 1 Mean change in body mass index (BMI) at years 1 to 5 from antiretroviral therapy (ART) initiation. BMI (kg/m2) was categorized as
underweight (< 18.5), normal (18.5–25), overweight (25–30) and obese (> 30). Data points represent mean change in BMI at each year, with year 0
being the time of ART initiation.
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ing injecting drug use (to address the concern that possible
secondary CVD events may have been misclassified as
primary events) [14]; (3) modelling the per cent change in
BMI rather than the absolute change; (4) further adjusting
models for DM outcome for blood glucose levels at study
entry.
All analyses were performed using STATA version 12
(STATA Corporation, College Station TX, USA).
Results
Patient characteristics
Figure S1 illustrates the patient selection for the CVD
models. A total of 9321 individuals (43 982 person-years)
were included in the analysis of the CVD outcome. At
D:A:D cohort entry, among the ART-naïve individuals,
those included (vs. those excluded because they did not
meet prior CVD criteria) were more likely to be younger,
female, diabetic, and past or never smokers (vs. current
smokers), and to have lower total cholesterol. Pre-ART BMI
was measured within 3 months previous to ART initiation
in the majority (79%) of individuals. Post-ART BMI
was measured within a median of 40 days [interquartile
range (IQR) 19 to 72 days] around the 1 year post-ART
time-point.
Table 1 provides characteristics at the time of ART ini-
tiation for patients included in the CVD analysis, overall
and by pre-ART BMI category. The majority were of normal
Table 1 Patient characteristics and incidence rates by pre-antiretroviral therapy (ART) body mass index (BMI) category for patients included in the
cardiovascular disease (CVD) analysis
Variable All (% of total)
Underweight






(BMI > 30 kg/m2)
Number of patients [n (%)] 9321 572 (6.1) 5994 (64.3) 2166 (23.2) 589 (6.3)
Male sex [n (%)] 7009 (75.2) 364 (5.2) 4652 (66.4) 1679 (24.0) 314 (4.5)
Age (years)
[mean (± SD)]
39.6 (±10.1) 37.45 (±9.7) 39.2 (±9.9) 41.18 (±10.5) 40.1 (±10.9)
HIV exposure [n (%)]
MSM 4613 (49.5) 230 (5.0) 3192 (69.2) 1026 (22.2) 165 (3.6)
IDU 752 (8.0) 66 (8.8) 511 (68.0) 140 (18.6) 35 (4.7)
Heterosexual 3,155 (33.9) 195 (6.2) 1,847 (58.5) 817 (25.9) 296 (9.4)
Other/not known 801 (8.6) 81 (10.1) 444 (55.4) 183 (22.9) 93 (11.6)
Ethnicity [n (%)]
White 3139 (33.7) 147 (4.7) 2098 (66.8) 717 (22.8) 177 (5.6)
Nonwhite 950 (10.1) 67 (7.0) 500 (52.6) 266 (28.0) 117 (12.3)
Not known 5232 (56.1) 358 (6.8) 3396 (64.9) 1183 (22.6) 295 (5.6)
Smoking [n (%)]
Current 3269 (35.1) 227 (6.9) 2266 (69.3) 638 (19.5) 138 (4.2)
Past 1000 (10.7) 59 (5.9) 636 (63.6) 238 (23.8) 67 (6.7)
Never 2236 (23.9) 96 (4.3) 1393 (62.3) 589 (26.3) 158 (7.1)
Unknown 2816 (30.2) 190 (6.8) 1699 (60.3) 701 (24.8) 226 (8.0)
HCV coinfection [n (%)] 1086 (11.7) 73 (6.7) 750 (69.0) 204 (18.8) 59 (5.4)
HBV coinfection [n (%)] 491 (5.2) 26 (5.3) 329 (67.0) 112 (22.8) 24 (4.9)
Family history of CVD [n (%)] 473 (5.0) 29 (6.1) 289 (61.1) 118 (24.9) 37 (7.8)
Total cholesterol (mmol/L)
[mean (± SD)]
4.3 (±1.2) 3.95 (±1.0) 4.2 (±1.1) 4.4 (±1.3) 4.5 (±1.07)
HDL cholesterol (mmol/L)
[mean (± SD)]
1.07 (±0.4) 1.06 (±0.5) 1.07 (±0.4) 1.05 (±0.5) 1.04 (±0.4)
Systolic blood pressure (mm of Hg)
[mean (± SD)]
122.9 (15.0) 113.4 (14.0) 121.5 (14.2) 127.0 (14.8) 129.5 (18.3)
Diabetes mellitus [n (%)] 206 (2.2) 9 (4.4) 78 (37.9) 79 (38.4) 40 (19.4)
Prior AIDS-related event [n (%)] 1128 (12.1) 169 (13.0) 738 (65.4) 179 (15.9) 42 (3.7)
CD4 count (cells/μl)
[median (IQR)]
254 (154, 342) 170 (50, 290) 250 (150, 340) 270 (186, 360) 280 (191, 384)
Log10 HIV RNA (copies/mL)
[mean (± SD)]
4.5 (±1.0) 4.7 (±1.0) 4.6 (±1.0) 4.4 (±1.1) 4.3 (± 1.1)
BMI (kg/m2)
[median (IQR)]
23.0 (20.9, 25.5) 17.58 (16.8, 18.1) 22.1 (20.7, 23.4) 26.59 (25.7, 27.8) 32.27 (30.9, 34.7)
Change in BMI at 1 year post-ART
Mean (± SD) 0.67 (±2.0) 1.82 (±2.29) 0.78 (±1.79) 0.30 (±1.93) −0.01 (±2.78)
Median (IQR) 0.31 (−0.30, 1.50) 1.21(0, 2.98) 0.34(−0.13, 1.53) 0.00(−0.64, 1.13) 0.00 (−0.85, 1.09)
HBV, hepatitis B virus [infection defined as HBV surface antigen (HBsAg) positive]; HCV, hepatitis C virus (infection defined as antibody positive); HDL, high-
density lipoprotein; IDU, injecting drug use; IQR, interquartile range; MSM, men who have sex with men; SD, standard deviation.
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weight, male and white, and they had a mean age of 39.6
years and a median CD4 count of 254 cells/μL. A large
proportion (> 40%) were reported to be current or ever
smokers. The median year of starting ART was 2006 (IQR
2003–2008). A total of 52.4% started on an NNRTI-based
regimen (of whom 77.3% received efavirenz) and 41.5% on
a PI-based regimen. A total of 49.9% received tenofovir,
32.4% received zidovudine and 9% received abacavir.
Factors associated with change in BMI at 1 year post-
ART are shown in Table 2. Lower pre-ART BMI, male sex,
use of PI (vs. NNRTI) in the initial regimen, older age,
previous/never smoking (vs. current smoking) and higher
CD4 count at ART initiation were associated with a smaller
gain in BMI. The overall mean change in BMI at 1 year
post-ART was a gain of 0.67 kg/m2. Figure 1 shows the
mean change in BMI at years 1 to 5 post-ART by pre-ART
BMI category using all of the available data. It appears that
underweight people continued to gain BMI, those with a
normal weight gained BMI which then remained relatively
stable or increased only slightly over time, while those with
a high BMI experienced a more stable BMI or a slight
weight loss over time.
Change in BMI at 1 year post ART initiation and
CVD outcome
By the end of follow-up, there were 97 CVD events (includ-
ing 46 MIs, 33 strokes and 18 invasive vascular procedures)
at a rate of 2.21/1000 person-years [95% confidence inter-
val (CI) 1.76–2.68/1000 person-years]. The median overall
follow-up time was 5.3 years (IQR 3.8–7.5 years), which
was similar within each pre-ART BMI category. Table 3
shows rates of CVD by quartiles of change in BMI overall
and by each pre-ART BMI category. The overall rate tended
to increase with increasing pre-ART BMI (Table 3).
The relationship between change in BMI and the risk of
CVD outcomes, shown in Table 3 and Figure 2, signifi-
cantly differed by pre-ART BMI category (P for interaction
between pre-ART BMI category and BMI change: < 0.05 in
all models). In the models adjusted for only demographic
factors (including pre-ART BMI), the incidence rate ratio
(IRR) (95% CI) per unit gain in BMI in those with normal
pre-ART BMI was 1.20 (1.07 to 1.34), which was only
slightly attenuated in fully adjusted models accounting for
known CVD risk factors. Categorizing pre-ART BMI into
quartiles (Fig. 2b) or further dividing the normal weight
category (Table S1) suggested that individuals with pre-
ART BMI in the middle range (middle two quartiles or
normal weight, high) experienced an increase in the risk of
CVD events per unit gain in BMI. Those with low pre-ART
BMI [ < 20.95 (quartiles) or < 18.5 (alternative categories)]
may have slightly lowered their risk of CVD per unit gain
in BMI, while those with high pre-ART BMI [ > 25.5
(quartiles) or > 30 (alternative categories)] did not experi-
ence a significant change in their risk of CVD events per
unit change in BMI.
Change in BMI at 1 year post ART initiation and
diabetes mellitus
Patient selection and characteristics were similar to those
for CVD outcome (not shown). A total of 125 DM events
occurred in 9193 eligible individuals (43 278 person-years),
at the rate of 2.89/1000 person-years (95% CI 2.40–3.44/
1000 person-years). The rates per 1000 person-years (95%
CI) by pre-ART BMI category were as follows: underweight,
2.04 (0.76–4.53); normal weight, 2.01 (1.51–2.59); over-
weight, 4.05 (2.88–5.54); and obese, 9.97 (6.32–14.96).
The incidence rates (95% CI) by quartiles of change in
BMI in all patients were as follows: first quartile, 2.11
(1.32–3.20); second quartile, 3.22 (2.20–4.54); third
Table 2 Multivariable model for factors associated with body






BMI at ART initiation
Underweight (< 18.5 kg/m2) 0.91 (0.75 to 1.08) <0.001
Normal (18.5–25 kg/m2) Reference
Overweight (25–30 kg/m2) −0.47 (−0.56 to −0.37) <0.001
Obese (> 30 kg/m2) −0.72 (−0.88 to −0.56) <0.001
PI or NNRTI in the initial regimen
NNRTI Reference
PI 0.2 (0.12 to 0.29) <0.001
Both NNRTI and PI in regimen 0.11 (−0.10 to 0.31) 0.32
None 0 (−0.27 to 0.26) 0.99
Age per 5-year increase 0.04 (0.02 to 0.06) <0.001
CD4 count at ART initiation
<200 cells/μL Reference
200–350 cells/μL −0.71 (−0.80 to −0.62) <0.001
>350 cells/μL −0.81 (−0.91 to −0.70) <0.001
Missing −0.22 (−0.61 to 0.16) 0.25
Smoking
Current Reference
Previous 0.19 (0.06 to 0.33) 0.005
Never 0.31 (0.20 to 0.42) <0.001
Unknown 0.3 (0.18 to 0.41) <0.001
Mode of transmission
Homosexual Reference
IDU 0.09 (−0.07 to 0.24) 0.28
Heterosexual 0.29 (0.18 to 0.40) <0.001
Other/unknown 0.25 (0.10 to 0.41) 0.002
Sex
Female Reference
Male 0.1 (0.00 to 0.22) 0.05
The model was adjusted for clinical cohort.
CI, confidence interval; IDU, injecting drug use; NNRTI, nonnucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
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quartile, 2.10 (1.32–3.12); and fourth quartile, 4.05 (3.00–
5.37). Figure 3 shows results from adjusted analyses for the
DM outcome, overall and by pre-ART BMI. A unit gain in
BMI was associated with an IRR (95% CI) of 1.13 (1.05–
1.23) in the models adjusted for demographical factors and
pre-ART BMI. This relationship was only mildly attenuated
in the fully adjusted models accounting for known risk
factors for DM. The IRR per unit gain in BMI tended to only
slightly vary by the pre-ART BMI (P value for heterogene-
ity in IRR across BMI categories: > 0.05 in all models).
Results were not sensitive to alternative categorization of
BMI (Table S2).
Sensitivity analyses
Results were robust to all of the sensitivity analyses for
both the outcomes. Excluding injecting drug users
(n = 752) made the trend of increasing rates (per 1000
person-years) (95% CI) of CVD with quartile of BMI change
in the normal pre-ART BMI category more apparent: first
quartile, 0.83 (0.27–1.93); second quartile, 1.94 (1.00–
3.39); third quartile, 2.09 (1.14–3.50); and fourth quartile,
3.32 (2.12–4.94). The IRR per unit gain in BMI for the
normal pre-ART BMI category was 1.23 (1.09 to 1.38)
(Table S3 shows results for the fully adjusted model).
Results for DM outcome did not change substantially (not
shown).
When the per cent change in BMI was modelled, a 1%
increase in BMI was associated with an IRR (95% CI) of
CVD as: 1.04 (95% CI 1.01–1.08) and 1.06 (95% CI 1.02–
1.11) in the middle two quartiles of the pre-ART BMI,
respectively (P = 0.01 for interaction between pre-ART BMI
and BMI change in fully adjusted models). Finally, for
diabetes outcome, a 1% increase in BMI in fully adjusted
models was associated with an IRR (95% CI) of 1.03 (1.01–
1.04) (P = 0.009), regardless of pre-ART BMI. Results were
also robust to further adjustment for blood glucose at study
entry (data not shown).
Discussion
The relationship between short-term gain in BMI after ART
initiation and long-term subsequent risk of CVD outcomes
varied by the pre-ART BMI. Those with pre-ART BMI in the
normal or middle two quartile categories experienced an
increase of approximately 18–20% in the risk of CVD per
unit gain in BMI. Those at the lower extreme possibly
benefited while those in the upper extremes did not experi-
ence any appreciable change in their already higher risk.
For the DM outcome, each unit gain in BMI was associated
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These associations did not disappear after adjusting for
previously identified key risk factors for each outcome.
Our findings are consistent with a previous report from
the VA cohort for the DM outcome, and further add to
evidence of the importance of the gain in BMI after ART
initiation for the long-term risk of CVD. To put our findings
in clinical context, a 40-year-old man with a BMI of
24 kg/m2 who is a current smoker, is ART-naïve, and has a
systolic blood pressure of 130 mm/Hg and total/HDL cho-
lesterol of 6/1 mmol/L, respectively, will have a 2.5% risk
of CVD in the next 5 years (according to the D:A:D risk
calculator [12]). A gain of 1 unit of BMI would increase this
risk to 3%, an increase of 20% in relative terms. Thus, the
total rise in absolute risk may not be large depending on
the background risk. However, given the expected timing
of BMI change around ART initiation, these observations
may help to better strategize risk factor management in this
high-risk population.
ART initiation, leading to viral suppression and CD4
count gain, often results in weight gain. Possible mecha-
Fig. 2 Adjusted incidence rate ratio (IRR) for cardiovascular disease (CVD) per unit gain in body mass index (BMI) at 1 year post antiretroviral therapy
(ART) initiation overall and by pre-ART BMI. Pre-ART BMI was categorized using the World Health Organization (WHO) classification (a) or quartiles
(b). Diamond: models were adjusted for pre-ART BMI category, cohort, sex, mode of transmission, family history of CVD, CD4 count at ART initiation
and age and smoking status as measured at analysis entry. P for effect modification: (a) 0.02; (b) 0.004. Triangle: models were additionally adjusted
for total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, diabetes, current use of abacavir, and cumulative use of
indinavir and lopinavir/ritonavir as measured at analysis entry. P for effect modification: (a) 0.04; (b) 0.01. Circle: models were adjusted for all of the
above variables (including specific ART agents mentioned above) as well as calendar year in a time-updated fashion where possible. P for effect
modification: (a) 0.04; (b) 0.01. In (a), the IRRs (95% confidence intervals) for the pre-ART BMI in the final model, with normal weight as the reference
category, were as follows: underweight, 1.53 (0.49–4.72); overweight, 1.07 (0.64–1.80); and obese, 1.10 (0.48–2.54).
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nisms include a reduction in metabolic requirements as
well as inflammation in those with suppressed viral load, a
return to good health and a resumption of “normal” life-
styles and, possibly, the effects of individual ART classes or
agents. In our exploratory analysis, receipt of a drug from
the PI class was associated with a greater gain in weight
compared with receipt of the NNRTI class. This was also
observed in the 1917 cohort but not in the Swiss cohort
[1,4].
The mechanistic link between this weight gain and out-
comes is also unclear. As seen in our exploratory analysis,
this gain in BMI appeared to be sustained over time (con-
sistent with the 1917 cohort as well as the Swiss cohort)
[1,4], especially in those who were underweight or of
normal weight at baseline, and this may contribute to their
CVD and DM risk [15]. Adjustments for factors potentially
on the causal pathway (such as lipids and blood pressure)
resulted in only a mild attenuation of the IRRs, suggesting
that the observed association is unlikely to be fully
explained by BMI-induced changes in these markers. Also,
in the VA cohort, the risk of DM per unit gain in BMI in
HIV-positive individuals was double the risk in HIV-
negative matched controls with a similar gain in BMI [7].
While ART initiation is known to reduce inflammation, one
recent study suggested that those initiating ART at normal
or higher BMI and subsequently gaining weight do not
experience a reduction in inflammation (or even have an
increase in inflammation), suggesting a role of ongoing
inflammation related to weight gain [16]. Future studies
should investigate how these risk factors interact and
evolve over time to impact the risk of CVD and DM in this
high-risk population.
While the finding that weight gain in underweight indi-
viduals had a minimal association with CVD outcomes was
expected, the finding that weight gain in those with high
pre-ART BMI also seemed to lack an association with CVD
outcome was unexpected. This finding should be interpreted
with caution. First, all our analyses were adjusted for
pre-ART BMI and, indeed, CVD rates were higher in those
with greater pre-ART BMI. These individuals were also at a
higher risk of DM, which is an important risk factor for CVD.
The actual gain in BMI over time in those with high pre-ART
BMI was minimal, with an average loss in BMI, in the obese
group. Also, relatively few individuals had a high BMI,
thereby limiting our power to detect associations or effect
modifications. It is also possible that those with high BMI
received prompter medical attention when required, and
those events were more likely to be prevented. Finally, BMI
may not accurately capture body fat [11]. Waist-to-hip ratio,
if available, might be a better indicator of central obesity
and could complement the information provided by BMI
[11]. Unfortunately, waist-to-hip ratio is often difficult to
measure, and was not available in our study.
The strengths of our study include a large heterogeneous
multi-country cohort, with well-validated (through estab-
lished protocols) outcomes. Also, we were able to account
Fig. 3 Adjusted incidence rate ratio (IRR) for diabetes mellitus (DM) per unit gain in body mass index (BMI) at 1 year post-antiretroviral therapy (ART)
initiation overall and by pre-ART BMI. Diamond: the model was adjusted for pre-ART BMI category, cohort, sex, mode of transmission, CD4 count
at ART initiation and age as measured at analysis entry. P for effect modification: 0.57. Triangle: the model was additionally adjusted for triglycerides,
high-density lipoprotein (HDL) cholesterol, systolic blood pressure and lipodystrophy as measured at analysis entry. P for effect modification: 0.65.
Circle: the model was adjusted for all of the above variables as well as calendar year in a time-updated fashion where possible. P for effect
modification: 0.83. The IRRs (95% confidence intervals) for the pre-ART BMI in the final model, with normal weight as the reference category, were
as follows: underweight, 0.96 (0.41–2.26); overweight, 1.70 (1.12–2.59); and obese, 4.19 (2.49–7.03).
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for several key potential confounders in a time-updated
fashion, including smoking and the use of specific ART
agents. Further, this analysis included data from an
ongoing modern cohort initiating ART with contemporary
regimens at a relatively high CD4 count, with only a
handful starting with thymidine analogues. This makes our
findings more generalizable to the modern ART era.
The study has a few limitations. First, the cohort was a
selected sample nested in a large cohort, which may limit
generalizability. Secondly, many lifestyle factors, such as
diet and exercise habits, were unavailable. Thirdly,
although the D:A:D study follows a rigorous outcome vali-
dation process, it is possible that some CVD events, in
particular MIs, could in fact be secondary events. However,
secondary MIs are known to be largely associated with
injecting drug use [14,17]. In our study, when we excluded
individuals exposed to HIV through injecting drug use, we
found that the association between BMI gain and CVD was
stronger. Finally, we could not analyse specific CVD events,
mainly because of limited power.
In conclusion, we found that the short-term gain in BMI
post ART initiation could be associated with the increased
risk of CVD, but only in those with normal or in middle two
quartiles of pre-ART BMI. The short-term gain in BMI post
ART initiation was also associated with increased risk of DM,
regardless of pre-ART BMI. Clinicians need to be aware that,
while traditionally thought to be a good prognostic factor in
people with HIV infection, excess weight gain post ART
initiation could be detrimental to future cardiometabolic
health. Also, given that this weight gain is expected to occur
in a window after ART initiation, it could provide clinicians
with an opportunity to consider interventions to pre-empt
the risk of these events. Finally, the role of sustained weight
gain over time in terms of cardiometabolic outcomes needs
further exploration. Ultimately, to answer the question of
whether weight-control interventions in the post-ART ini-
tiation period truly decrease the risk of outcomes, a
randomized trial will be needed.
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Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel
Aviv; S Pollack, G Hassoun, Rambam Medical Center,
Haifa; S Maayan, Hadassah University Hospital, Jerusalem.
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Trocha, Medical University, Gdansk; E Jablonowska, E
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Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz,
Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.
Romania: (D Duiculescu), Spitalul de Boli Infectioase si
Tropicale: Dr Victor Babes, Bucarest.
Russia: (A Rakhmanova), Medical Academy Botkin Hos-
pital, St Petersburg; N Zakharova, St Petersburg AIDS
Centre, St Peterburg; S Buzunova, Novgorod Centre for
AIDS, Novgorod.
Serbia: (D Jevtovic), The Institute for Infectious and
Tropical Diseases, Belgrade.
Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bra-
tislava.
Slovenia: (J Tomazic), University Clinical Centre Lju-
bljana, Ljubljana.
Spain: (J González-Lahoz), V Soriano, P Labarga, J
Medrano, Hospital Carlos III, Madrid; S Moreno, JM Rod-
riguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R
Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i
Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i
Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo,
MA Sambeat, Hospital Sant Pau, Barcelona.
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Stockholm; L Flamholc, Malmö University Hospital,
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